October 30, 2007

PDL BioPharma

From a MF write-up:

PDL BioPharma's [Nasdaq: PDLI] drug Nuvion, a novel treatment for severe ulcerative colitis, which is a large market with zero competition. As first mover, Nuvion -- once it gets the nod from the FDA -- should nab a decent share of a huge market and become a blockbuster.

No comments: